JP2022515239A5 - - Google Patents

Info

Publication number
JP2022515239A5
JP2022515239A5 JP2021536323A JP2021536323A JP2022515239A5 JP 2022515239 A5 JP2022515239 A5 JP 2022515239A5 JP 2021536323 A JP2021536323 A JP 2021536323A JP 2021536323 A JP2021536323 A JP 2021536323A JP 2022515239 A5 JP2022515239 A5 JP 2022515239A5
Authority
JP
Japan
Prior art keywords
cancer
lymphoma
hydroxymethyl
tris
cell lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021536323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515239A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067897 external-priority patent/WO2020132471A1/en
Publication of JP2022515239A publication Critical patent/JP2022515239A/ja
Publication of JP2022515239A5 publication Critical patent/JP2022515239A5/ja
Priority to JP2024131002A priority Critical patent/JP7749080B2/ja
Priority to JP2025156833A priority patent/JP2026001058A/ja
Pending legal-status Critical Current

Links

JP2021536323A 2018-12-21 2019-12-20 有機化合物の結晶および塩形態およびその医薬組成物 Pending JP2022515239A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024131002A JP7749080B2 (ja) 2018-12-21 2024-08-07 有機化合物の結晶および塩形態およびその医薬組成物
JP2025156833A JP2026001058A (ja) 2018-12-21 2025-09-22 有機化合物の結晶および塩形態およびその医薬組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US62/784,083 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US62/791,571 2019-01-11
US201962882712P 2019-08-05 2019-08-05
US62/882,712 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024131002A Division JP7749080B2 (ja) 2018-12-21 2024-08-07 有機化合物の結晶および塩形態およびその医薬組成物

Publications (2)

Publication Number Publication Date
JP2022515239A JP2022515239A (ja) 2022-02-17
JP2022515239A5 true JP2022515239A5 (cg-RX-API-DMAC7.html) 2022-12-26

Family

ID=69185721

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021536323A Pending JP2022515239A (ja) 2018-12-21 2019-12-20 有機化合物の結晶および塩形態およびその医薬組成物
JP2024131002A Active JP7749080B2 (ja) 2018-12-21 2024-08-07 有機化合物の結晶および塩形態およびその医薬組成物
JP2025156833A Pending JP2026001058A (ja) 2018-12-21 2025-09-22 有機化合物の結晶および塩形態およびその医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024131002A Active JP7749080B2 (ja) 2018-12-21 2024-08-07 有機化合物の結晶および塩形態およびその医薬組成物
JP2025156833A Pending JP2026001058A (ja) 2018-12-21 2025-09-22 有機化合物の結晶および塩形態およびその医薬組成物

Country Status (22)

Country Link
US (2) US12297179B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898597A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022515239A (cg-RX-API-DMAC7.html)
KR (1) KR20220035022A (cg-RX-API-DMAC7.html)
CN (1) CN113508108B (cg-RX-API-DMAC7.html)
AU (1) AU2019403396B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012305A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001640A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009309A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210394A (cg-RX-API-DMAC7.html)
GE (2) GEP20247683B (cg-RX-API-DMAC7.html)
IL (1) IL284218B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210147A1 (cg-RX-API-DMAC7.html)
MA (1) MA54541A (cg-RX-API-DMAC7.html)
MX (1) MX2021007536A (cg-RX-API-DMAC7.html)
NI (1) NI202100055A (cg-RX-API-DMAC7.html)
PE (2) PE20260309A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551495A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106526UA (cg-RX-API-DMAC7.html)
TW (1) TWI875727B (cg-RX-API-DMAC7.html)
UA (1) UA130491C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020132471A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7622000A (en) * 1999-10-01 2001-05-10 Institute Of Molecular And Cell Biology Compounds for the treatment of viral-mediated diseases
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
MX2010010300A (es) 2008-03-19 2010-10-26 Osi Pharm Inc Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
US20230285364A1 (en) * 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Similar Documents

Publication Publication Date Title
IL283184B2 (en) Crystal polymorph of (7s,13r)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10] benzoxatriazacyclotridecin–4(5h)–one for the treatment of cancer
EP3604294B1 (en) Compounds and compositions for modulating egfr mutant kinase activities
TW201806598A (zh) 治療癌症及骨癌疼痛之方法
JP2021512131A5 (cg-RX-API-DMAC7.html)
RU2017141035A (ru) Твердые формы соединения, модулирующего киназы
EA020022B1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
JP2018515490A5 (cg-RX-API-DMAC7.html)
CN115624550B (zh) 一种用于治疗胃癌的喹啉衍生物
HRP20230477T1 (hr) Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze
CN111012785B (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途
IL299099B1 (en) Combinations of cancer treatments
RU2010121647A (ru) Полиморфы ингибитора c-met/hgfr
JP2018534289A5 (cg-RX-API-DMAC7.html)
CN111818925A (zh) Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途
JP2016513704A5 (cg-RX-API-DMAC7.html)
JP2022058492A (ja) N-(2-(2-(ジメチルアミノ)エトキシ)-4-メトキシ-5-((4-(1-メチル-1h-インドール-3-イル)ピリミジン-2-イル)アミノ)フェニル)アクリルアミドおよびその塩の医薬製剤
JP5858989B2 (ja) 組合せ
EP2874615A1 (en) Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg
RU2004110042A (ru) Тиено[2,3-d] пиримидины с комбинированной агонистической активностью lh и fsh
CN113597309B (zh) 抗肿瘤组合物
JP2014005265A5 (cg-RX-API-DMAC7.html)
EP3471730B1 (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
JP2022502484A (ja) キナーゼ阻害活性を有する芳香族複素環式化合物
TWI374880B (en) A pharmaceutically acceptable salt and solvate of n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methylmethanesulfonamide and uses thereof
Mansour et al. Dual topoisomerase IIα/EGFR-TK inhibitors: Synthesis, biological evaluation, and in silico studies of new thiadiazolo [3, 2-a] pyrimidinone derivatives as potential anticancer agents